Trial Profile
An Open-label, Multi-centre, Observational, Post-marketing Surveillance to Monitor the Safety of REQUIP(Ropinirole) Administered in Korean Restless Leg Syndrome Patients According to the Prescribing Information
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions
- Acronyms REQUIP RLS PMS
- Sponsors GSK
- 15 Sep 2017 New trial record